Context Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Context Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 3.0 times its market value (net cash). Higher than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-235.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 93% of Healthcare companies in United States.
Cash Cushion Ratio
3.0× cashCash, after subtracting all debt, is 3.0 times its market value (net cash).
Higher than 98% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Context Therapeutics Inc. made a loss over the last year. Context Therapeutics Inc. owes $0.17 for every $1 it owns. Context Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossContext Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.57The share price is 0.57 times Context Therapeutics Inc.'s book value per share, lower than 89% of Healthcare companies in United States.
Market cap
$22 MThe total market value of all of Context Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 81% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$38 MWhat Context Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.42Net worth divided by the number of shares. The share price of $0.24 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-76.1%Context Therapeutics Inc. lost 76.1% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
Owes vs Owns
0.17×Context Therapeutics Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Dividend yield
NoneContext Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossContext Therapeutics Inc. made a loss in each of the last two years.
Cash vs debt
Net cashContext Therapeutics Inc. held $66 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Context Therapeutics Inc.: $22 M ÷ $38 M (30 Jun 2026) = 0.6.
What is Context Therapeutics Inc.'s return on equity?
Context Therapeutics Inc. lost 76.1% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
How much does Context Therapeutics Inc. owe compared with what it owns?
Context Therapeutics Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Does Context Therapeutics Inc. pay a dividend?
No. Context Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.